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This article summarizes and provides commentary
regarding current guidelines on the administration
of immunotherapy (IT) for allergic airway disease.
Details on currently accepted practices in the
preparation and administration of IT are published
elsewhere,1–5 and allergy practitioners are advised
to use these references as the standard of care. This
article draws primarily on recent studies regard-
ing the current understanding of the mechanism
and proper administration of IT (with emphasis on
the importance of properly dosing major allergen
content) and on current insights into the selection
of patients and allergens for IT. Finally, several
recent studies have reported on issues of morbid-
ity and mortality associated with IT and empha-
size particularly the importance of postponing
administration of IT at times when asthma is
poorly controlled.
Review
Update on Allergy Immunotherapy
William Davidson, MD; Sean Lucas, MD; Larry Borish, MD
Abstract
This article summarizes and provides commentary regarding guidelines on the administration of
immunotherapy (IT) for allergic airway disease. Recent investigations have provided important insights
into the immunologic mechanism of IT and the prominent role of interleukin-10–producing regulatory T
lymphocytes. The most important aspect of successful IT is the administration of an appropriate dose
of an extract containing a sufficient concentration of the relevant allergen. This is largely possible now
only with standardized extracts. When the major allergen content of successful IT extracts was quanti-
fied, efficacy was demonstrated across a surprisingly narrow concentration range (approximately 
5–24 µg per injection), irrespective of the extract. This presumably reflects the concentration of an anti-
gen that drives an immune response toward tolerance. It may be predicted that as major allergen con-
tent is quantified in currently nonstandardized extracts, effective IT will also be achieved by administer-
ing a dose in this range, in contrast to current practices involving fairly arbitrary dosing decisions. With
the availability of nonsedating antihistamines, intranasal corticosteroids, and the leukotriene modifiers,
inadequate pharmacologic response or intolerable side effects are less commonly the major indications
for starting IT for allergic rhinitis (AR). However, with the recognition that a relatively short course 
(3–5 years) of IT can provide long-term immunomodulation and clinical benefit, a desire to avoid long-
term pharmacotherapy and the associated high costs may be the primary indication for IT in AR cases.
While evidence overwhelmingly supports the beneficial influences of IT in asthma cases, the position-
ing of IT for this disorder is not established. The observed prevention of asthma in children who have
AR is intriguing, but further studies are required to assess the extent to which the prevalence and sever-
ity of chronic asthma will be reduced when these children reach adulthood. Similarly, safety issues over-
whelmingly suggest that uncontrolled asthma is the greatest risk factor for mortality associated with IT
and that IT therefore may be contraindicated for most patients who have inadequate pharmacologic
responses or are unable to tolerate useful pharmacologic agents. Paradoxically, these are the patients
for whom a response to IT may be most desirable.
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Mechanisms of Immunotherapy
Several mechanisms of IT have emerged over
recent decades, reflecting an increased under-
standing of immunology. Early studies concen-
trated on increases in allergen-specific
immunoglobulin (Ig) G, specifically that of the
IgG4 isotype. These immunoglobulins were pro-
posed as “blocking” immunoglobulins that com-
peted with IgE for allergen binding to IgE recep-
tor–expressing cells. However, the correlation
between IgG concentrations and clinical response
to treatment is weak, and even when correlated to
nasal IgG (or IgA) concentrations in the allergic
inflammatory milieu, no improvements in these
relationships were observed.
More recently, immunodeviation has been
cited, with reductions in T-cell proliferative
responses to allergens and a shift from a T-helper
2 (Th2)–like response toward a Th1-like response
following immunotherapy.6 Unfortunately, this
model also comes under scrutiny because (1) T
cells that produce interferon (INF)- (Th1-like
cells) are a characteristic feature of allergic inflam-
mation, (2) IFN- is a potent proinflammatory
compound that contributes to both the presence and
severity of allergic disease,7 and (3) subsequent
studies have failed to consistently confirm these
findings. In contrast, the one consistent finding
observed after IT is diminished responsiveness
(tolerance) of the allergen-specific Th2-like cells.
As such, a potentially more valid model attrib-
utes the mechanism of IT to the induction of T cells
with regulatory activity. Several classes of regula-
tory T cells have been described (Table 1), includ-
ing IL-10–producing lymphocytes (termed “Tr1
cells”), CD25+ T regulatory (Treg) cells, and Th3
cells that produce transforming growth factor beta
(with or without IL-10). Thymus-derived CD25+
Treg cells are important for the induction of toler-
ance to self-antigens and the prevention of autoim-
munity. Th3 cells are primarily ascribed to mucosal
tolerance. Whereas these latter two cell groups are
therefore unlikely to be involved in allergen IT,
induction of Tr1 cells may play a key role in reduc-
ing allergen-specific T-cell responsiveness.
Aprominent role for IL-10–producing activated
CD4+ cells was first described in studies involving
bee venom IT.8 Subsequent investigations with house
dust mite IT extended the importance of IL-10 (and
transforming growth factor beta [TGF-]) produc-
tion by CD4+ Tcells to inhalant allergy and confirmed
that this occurred in parallel to the suppression of Th2
proliferative responses and cytokine production.9
In this study, IL-10 responses in healthy nonatopic
individuals who had been exposed to allergen were
similar to those in the IT-treated group, implying the
restoration of tolerant T-cell responses in the atopic
Table 1  CD4+ T Cells with Regulatory Activity
Regulatory T Cell Characteristics
Treg CD25+ foxp3+ thymus derived
Not dependent on IL-10 for biologic activity
Mediates self-tolerance; prevents autoimmune disease
Not likely to be relevant to acquired tolerance to allergens
Th3 Characterized by TGF- (±IL-10) production
Mediates mucosal tolerance/antigen-specific IgA production
Not relevant to allergy or immunotherapy
Tr1 Peripheral-derived regulatory T cells
IL-10 responsible for biologic activity (± TGF-)
Possibly derived from Th1- or Th2-like lymphocytes or natural T cells
CD25 expression (reflecting activation)
Foxp3 negative
Proposed mechanism of immunotherapy
IgA = immunoglobulin A; IL-10 = interleukin-10; TGF- = transforming growth factor beta; Th = T helper; Tr1 = peripher-
ally-derived regulatory T cell; Treg = thymic-derived regulatory T cells.
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individual. Other studies have also shown IL-10
production by CD4+ cells without changes in grass
pollen–induced proliferation or Th2 cytokine pro-
duction.10 This area of research remains confused;
for example, although a role for CD25 expression
has been ascribed to these IL-10–producing cells, it
is unclear whether this reflects the constitutive
expression of this component of the IL-2 receptor that
is the signature characteristic of Treg cells or whether
this reflects the induced expression of this compo-
nent of the IL-2 receptor as occurs with activation
of these effector T cells. However, what is consis-
tent is that each of these studies has found cells
capable of making high levels of IL-10 (with or
without TGF-) consistent with the Tr1 cell type, and
current concepts therefore focus on the integral role
of these IL-10–producing cells in immune toler-
ance to allergens after IT.
Indications for Aeroallergen IT
Although allergen IT is effective as a treatment of
allergic rhinitis and allergic asthma, considera-
tions reflecting its variable degree of therapeutic
benefit and safety have led to the absence of con-
sistent recommendations regarding indications
for allergen IT for these conditions. A task force
representing the American Academy of Allergy,
Asthma and Immunology and the American Col-
lege of Allergy, Asthma & Immunology recently
published evidence-based guidelines regarding
indications for IT for inhaled allergens (Table 2),5
and similar recommendations were previously
published by the Canadian Society of Allergy and
Clinical Immunology.1
Allergic Rhinitis
Less controversy surrounds the use of IT for aller-
gic rhinitis (AR).2–4,11–15 Clearly, an absolute pre-
requisite for initiating IT is documentation of
symptomatic disease, with evidence of specific IgE
antibodies as shown by skin testing or by IgE
immunoassays. Historically, the most important
indications for IT were the combination of either
a poor response to pharmacotherapy or allergen
avoidance and unacceptable adverse effects from
available medications. Given all of the limita-
tions of allergen avoidance and the frequently
inadequate relief provided by antihistamines, IT
was often the best treatment available during the
era when the only available agents for AR were
sedating antihistamines. The introduction of sec-
ond-generation nonsedating antihistamines gen-
Table 2  Clinical Indications for Allergen Immunotherapy
Allergic rhinitis
Symptoms of allergic rhinitis with natural exposure to allergens, evidence of clinically relevant 
IgE antibodies, and one of the following:
Poor response to pharmacotherapy or allergen avoidance
Unacceptable adverse effects of medications
Desire to avoid long-term pharmacotherapy and reduce the cost of medication
Coexisting allergic rhinitis and asthma
Possible prevention of asthma in children*
Allergic asthma
Symptoms of allergic asthma with natural exposure to aeroallergens, evidence of clinically relevant 
IgE antibodies, and one of the following:
Poor response to pharmacotherapy or allergen avoidance*
Unacceptable adverse effects of medications*
Desire to avoid long-term pharmacotherapy and reduce the cost of medication*
Coexisting allergic rhinitis and asthma
Adapted from Joint Task Force on Practice Parameters5; Canadian Society of Allergy and Clinical Immunology.1
IgE = immunoglobulin E.
*Controversial (see text for discussion).
erally eliminated intolerance to antihistamines as
an indication for IT. In addition, intranasal corti-
costeroids were made available and were shown,
in frequent contrast to antihistamines, to be
extremely effective treatments of AR. Although
associated with local side effects, intranasal cor-
ticosteroids are generally well tolerated. More
recently, leukotriene modifiers have been studied
and have been shown to have some efficacy in
treating AR although their ultimate position in
treatment has not been determined. Thus, most
patients can achieve effective control of their AR
with pharmacologic treatments, without unac-
ceptable adverse effects. As such, in addition to
patients’ reluctance to use intranasal corticos-
teroids, the most important indication for initiat-
ing IT for AR is the patient’s desire to avoid long-
term pharmacotherapy and to reduce costs. This
finding is primarily supported by a seminal study
demonstrating that IT-induced relief from the
symptoms of grass pollen rhinitis persisted for at
least 3 years after the discontinuation of IT.16
Given supportive earlier studies suggesting that 3
to 5 years of IT can provide long-term benefits,17
the preference for short-term IT over life-long
pharmacotherapy may be the most important indi-
cation for recommending IT. Although cures are
unusual with IT, patients who are allergic to aller-
gens for which effective agents are available  can
expect significant clinical benefit when treated at
appropriate dosages (as discussed below). Thus,
many of these patients can hope to evolve from
being dependent on continuous multidrug therapy
(including topical corticosteroids) to perhaps being
manageable with as-needed antihistamines alone.
Clearly, 3 to 5 years of IT has cost benefits when
compared to lifelong pharmacotherapy. In addition,
although IT requires a significant time commitment
and is associated with a certain discomfort to the
patient, many patients will accept this commitment
in exchange for eliminating a lifelong dependence
on multidrug therapy.
The role of IT in patients with coexisting
asthma is discussed below. The indication that IT
can prevent the development of asthma in children
is intriguing but still controversial.18–20 This indi-
cation is based primarily on a multicentre study
of children with AR that found that 3 years of IT
for grass and/or birch pollen allergy could reduce
the risk of asthma developing later.20 This rec-
ommendation may not be wholly appropriate for
several reasons. Patients, particularly children,
with severe seasonal allergic rhinitis (SAR) often
have pulmonary complaints of cough and chest
tightness. However, these patients generally have
a fairly benign syndrome, and their lower airway
complaints often respond to whatever therapies are
offered for their SAR, including intranasal corti-
costeroids and antihistamines. This study pro-
vides compelling evidence that these patients do
in fact have asthma. What this study does not
establish is whether IT administered at this early
stage as treatment of AR can prevent the later
development of persistent (as opposed to “sea-
sonal”) asthma. Specifically, it is unknown whether
a difference in prevalence and severity of asthma
will persist after these patients reach adulthood.
Arguably, this study merely added IT to intranasal
corticosteroids and antihistamines as AR-directed
therapies that might mitigate this benign form of
“seasonal allergic asthma.” The frequency with
which asthma developed in this study far exceeded
what would be expected regarding the development
of asthma in an atopic cohort and may suggest that
the investigators were reporting on the mitiga-
tion of a less severe asthma variant. A second
study also reported that the risk of asthma symp-
toms was higher (threefold) in controls than in asth-
matic subjects who received IT.19 However, this
study did not demonstrate any differences in lung
function between experimental and control groups,
nor was there any significant difference between
the two groups in regard to the use of asthma
medications. Additional studies with longer-term
follow-ups are still required to confirm whether IT
administered in infancy can reduce the prevalence
of persistent asthma later in life.
Allergic Asthma
The second indication for IT for patients with
aeroallergen sensitization is for allergic asthma.
Although the efficacy of IT for asthma is viewed
as controversial and many studies provide con-
flicting evidence, the preponderance of data clearly
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supports a beneficial influence of IT in this dis-
order.15,21–25 Recent meta-analyses of approxi-
mately 75 asthma trials concluded that IT reduced
the use of asthma rescue medications and the fre-
quency of asthma symptoms.26,27 These studies
conceded, however, that the evidence gave limited
guidance regarding the size of the benefit relative
to that of other therapies. Because of  this and
because of safety concerns, the role of IT in aller-
gic asthma remains controversial. For example, the
first criterion listed in the guidelines, “poor
response to pharmacotherapy or allergen avoid-
ance,” is debatable, given safety issues. A poor
response to pharmacotherapy implies uncontrolled
asthma, and, as discussed below, uncontrolled
asthma is considered a virtually absolute con-
traindication to IT.
Although IT can improve asthma symptoms
and the need for a rescue -agonist,26 there have
been no well-performed controlled trials that have
confirmed the claim that the administration of IT
will help “avoid long-term pharmacotherapy and
reduce the cost of medication.”5 Specifically, what
has never been validated is the reasonable expec-
tation that IT might reduce a patient’s symptom
severity to such an extent that one or more long-
term controllers could be eliminated. Because the
greatest concern regarding adverse effects is for
those of oral and (arguably) inhaled corticosteroids,
it would be imperative to generate data showing the
ability of IT to eliminate the need for this class of
medication. For corticosteroid-dependent asthma
cases, the second criterion, like the first, is prob-
lematic insofar as asthma this severe should be
viewed as a virtually absolute contraindication to
starting IT. This leaves coexisting AR and (well-
controlled) asthma as the most important indica-
tions for IT for asthma. It is reasonable to admin-
ister IT to an AR patient whose asthma is well
controlled, with the recognition that the AR is
likely to substantially improve and that any sub-
sequent benefit to the asthma is an added “bonus.”
Efficacy of Allergy Immunotherapy
It is reasonable to speculate that since its incep-
tion, IT has been attempted with virtually all con-
ceivable aeroallergens. However, efficacy has
been established against only a relatively few
extracts; for many extracts, especially mould
extracts, the evidence for efficacy is sparse. In well-
designed placebo-controlled studies, efficacy has
been shown against ragweed, various grasses (tim-
othy, rye grass), trees (mountain cedar, birch),
dust mites, and cats. As discussed, significant
clinical improvement has been shown for subjec-
tive symptom and medication diary scores in com-
parison to the placebo group. Efficacy largely
requires definition of the nature of the specific aller-
gen and the development of a means of generat-
ing an extract with a concentration of the relevant
allergenic component sufficient to produce an
immunomodulating effect (dosing requirements are
discussed below). With pollens, defining the rel-
evant allergen—the pollen grain itself—and devel-
oping the botanic techniques to obtain that aller-
gen are relatively straightforward. Thus, the earliest
studies categorically establishing the efficacy of
IT were performed with ragweed, and subsequent
studies have shown positive results with northern
grasses and a few trees. The ability of studies to
show the efficacy of IT for ragweed was rendered
easier by the relative paucity of allergens respon-
sible for autumnal seasonal AR and by the dom-
inant role of ragweed in that disease. This is in con-
trast to tree allergy, for which obtaining a pollen
extract in concentrations sufficient to produce
efficacy should be straightforward; however, the
ability to document efficacy is confounded by an
inability to identify subjects that demonstrate sen-
sitization to only one or a few trees and by the con-
comitant presence of innumerable tree-derived
pollens, for example, in early spring in the east-
ern United States. The studies that have shown effi-
cacy in cases of tree allergy involved the treatment
of cohorts in locations where a single allergen
(eg, birch in Scandinavia or mountain cedar in
Texas) presented overwhelming and unique aller-
gic problems. Similarly, the efficacy of IT for
grass allergy is well established, reflecting the
cross-reactivity of the various northern grass pol-
lens and the relative paucity of confounding aller-
gens during the late spring season.
In contrast to the case of pollens, the ability
to show responsiveness to indoor allergens fol-
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lowed a more difficult course and was severely
confounded by the absence of a proper charac-
terization of the relevant allergenic proteins. Innu-
merable patients have received IT for “dust,”
extracts of which are at best described as “unstan-
dardized” and at worst represent a conglomeration
of numerous uncharacterized components, none of
which are present at sufficient concentrations to
provide any sort of clinical benefit. Only with the
recognition of dust mites as the dominant allergen
in indoor dust samples did it become possible to
develop standardized extracts in concentrations suf-
ficient to mediate clinical benefit. Similarly, the
availability of extracts with well-characterized
concentrations of the dominant cockroach-derived
allergens should make it possible to perform effec-
tive IT with these agents. Unfortunately, little
additional progress has been made in defining
other allergenic proteins likely to be present in
indoor dust samples and likely to be producing
symptoms in large cohorts of perennial AR sub-
jects. For example, in specific communities, aller-
gens such as those derived from spiders, “miller”
moths, and ladybugs may be extremely important
sources of allergic symptoms but remain an
untapped area of treatment.
Another area in which research has led to the
development of efficacious extracts is the treatment
of animal allergy. The treatment of subjects with
cat allergy is a revealing example of the difficul-
ties inherent in developing useful extracts and the
importance of proper investigations. Cats have
long been recognized as an important cause of AR,
and such AR has traditionally been ascribed to cat
dander, with little insight in regard to the term “dan-
der.” The assumption that the allergen was a pelt-
derived protein led to the development of extracts
derived from the skins of carefully cleaned animals.
The subsequent recognition that the dominant cat
allergen is a protein derived from skin glands led
to the recognition of the paradox that the com-
mercially available extracts were virtually devoid
of Fel d I and, as such, were worthless as
immunomodulating agents. Current standardized
extracts, with quantifiable levels of the dominant
cat allergen, have proved effective for cat allergy.
The treatment of dog allergy has lagged behind that
of cat allergy, but the recent characterization of the
dominant dog allergens has begun to make avail-
able extracts with sufficient concentrations of
these allergens to warrant investigations to docu-
ment their efficacy. Rodents, either as pets or as
pests, are an additional major source of animal-
derived allergens. The rodent glomerulus permits
the passage of small proteins, and these urinary pro-
teins are the primary source of allergens. As in the
case of cat allergy, only after the recognition that
urine and not dander was the source of the dom-
inant allergen has it become possible to develop
allergy extracts that contain sufficient concentra-
tions of relevant allergens to plausibly provide
efficacy. Continuing research has defined major
allergens in other mammals such as horses, cows,
and rabbits, and this presumably will lead to the
availability of useful extracts.
The one area of inhalant allergy that remains
a daunting problem has been the treatment of
mould allergies. Although a few studies have
shown efficacy of IT in mould-induced allergic dis-
ease caused by Alternaria and Cladosporium, the
preponderance of studies have not confirmed these
results, nor have these results been extended to the
innumerable other moulds. In part, this reflects the
apparent absence of a single dominant allergen
responsible for allergy caused by a given species
of mould. Thus, different species (or even strains)
of Alternaria have allergens that are sufficiently
different that their allergens do not provide cross-
protection when administered as IT. In fact, not
only do different strains of moulds produce suf-
ficiently different allergenic components to pre-
clude cross-reactive efficacy, but even the same
strain can express different allergenic proteins,
depending on variations in growth and environ-
mental conditions.
Dose and Duration
The efficacy of IT is entirely dependent on achiev-
ing an optimal therapeutic dose of each allergen.5
Low-dose IT (eg, Rinkel therapy) has proved inef-
fective. It is generally accepted that there is a
positive dose-response for most aeroallergen IT.
Historically, however, there has been no clear def-
inition as to what constitutes high- or moderate-
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dose IT because of a lack of consensus on mea-
surements of potency. Allergen standardization
has tremendously advanced our ability to repro-
ducibly administer effective IT extracts.3 Stan-
dardized extracts are currently available from dust
mites, several grasses, short ragweed, and cats
and have been evaluated for their major allergen
content (Table 3). Other allergen extracts, such as
those from dogs, cockroaches, and a few trees
and moulds, have not been fully standardized, but
at least information regarding the content of rel-
evant allergenic components is available.
With the standardization of allergenic extracts
and the availability of information regarding rel-
evant allergens, it became possible to quantify
the concentration of allergens used in studies
demonstrating the efficacy of IT. Maintenance
doses for allergens showing clinical efficacy are
summarized in Table 4. When these data became
available, the consistency of the doses showing
efficacy was an astounding observation with
important clinical significance. Virtually all of
the studies that showed efficacy demonstrated
this efficacy in a surprisingly narrow range of
concentrations—approximately 5 to 24 g per
dose of the major allergen. This has two impor-
tant implications. From an immunologic view-
point, this suggests that these are the concentra-
tions of antigen required to drive an immune
response into tolerance. Of greater relevance to
allergists is the implication that this might extend
to all allergens and that given information regard-
ing the concentration of major allergens, it should
be possible to predict the effective concentration
of any extract. Nonstandardized extracts continue
to be provided weight per volume or in protein
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Table 3  Major Allergen Content of US Standardized Extracts*†
Mean Content 
Allergen Extract Expressed Potency Major Allergen (μg/mL)
Grasses
Kentucky blue 100,000 BAU/mL Poa p 5 262
Timothy 100,000 BAU/mL Phl p 5 743
Orchard 100,000 BAU/mL Dac g 5 918
Fescue 100,000 BAU/mL Fes p 5 152
Rye 100,000 BAU/mL Lol p 5 337
Short ragweed 1:10 w/v Amb a I 268
‡1:20 w/v Amb a I 89
§1:10 w/v Amb a I 350–625
Mixed ragweed 1:10 w/v Amb a I 174
Dermatophagoides 10,000 AU/mL Der p I 172
pteronyssinus ‡10,000 AU/mL Der p I 78
‡30,000 AU/mL Der p I 182
Dermatophagoides farinae 10,000 AU/mL Der f I 44
‡10,000 AU/mL Der f I 68
‡30,000 AU/mL Der f I 293
Cat hair 10,000 BAU/mL Fel d I 40
‡10,000 BAU/mL Fel d I 60
§10,000 BAU/mL Fel d I 40–80
Dog hair 1:10 w/v Can f I 5.4
Acetone precipitated dog|| 1:50 w/v Can f I 189
AU = allergy units; BAU = bioequivalent allergy units; w/v = weight per volume.
*Sources of extracts: US Food and Drug Administration and extract laboratories.
†Values provided by ALK-Abello, Inc, Wallingford, CT.
‡Hollister-Stier Laboratories, Spokane, WA.
§Greer Laboratories, Lenoir, NC.
||Hollister-Stier Laboratories, Spokane, WA; now also available in 1:100 with similar Can f 1 values.
nitrogen units. At present, for these nonstandard-
ized allergens, the dose must be based on arbitrary
decisions regarding dilution, and this contributes
to their limited proven efficacy.
Several other issues pertain to the preparation
of extracts for administration. It is important to
avoid the inadvertent administration of subthera-
peutic doses resulting from dilution caused by mix-
ing multiple allergens. Current guidelines recom-
mend diluting all allergic extracts into the same
final volume, regardless of the number of allergens
included, and adjusting the volume of diluent in
accordance with this number of extracts. In addition,
surprisingly little is known at present regarding the
stability of these extracts. Loss of extract potency
is generally viewed as being accelerated by passage
of time, higher temperature, greater dilution, non-
glycerine-containing preservatives, allergens with
higher protease content, and (in some studies) use
of excessive volume for the storage vial. The major-
ity of published studies of concentrated extracts
preserved with 50% glycerin showed the extracts to
be stable for at least 12 months.28–33 In one study, sev-
eral allergens remained stable after storage for as long
as 36 months at 6°C.31 However, in contrasting
studies, the potency of Der p 1 and Der p 2 fell 50%
at 12 months,32 and another study found that 
Candida lost stability after only 10 weeks.34
Several studies have addressed the stability of
diluted extracts. Dilutions (1:100) of Russian thistle
solubilized in human serum albumin, glycerin, saline,
or phosphate buffer maintained potency for 
12 months.35 However, only extracts in glycerin
maintained potency at a 1:10,000 dilution. In a dif-
ferent study, temperature had no effect, and at 
3 months, diluted extracts that were stored at 4°C and
those that were brought to room temperature 
13 hours a week showed equivalent potency.36 At 
12 months, both groups had similarly reduced potency.
There were no differences in the residual potency
between single and mixed allergens except at dilutions
of 1:1000, at which there was greater preservation of
allergen potency with the three-allergen mix.
A more recent study addressed the influence
of dilution and antigen mixing on extract stabil-
ity.37 Potency was preserved at 3 months with sin-
gle-allergen extracts but was reduced by protease-
containing extracts; Alternaria had the broadest
degradation capacity, followed by cockroach and
Cladosporium. Glycerin protected the extracts
from the protease-containing allergens. The best
preservative was 50% glycerin, followed by 10%
glycerin and 0.03% human serum albumin.
In summary, concentrated extracts appear to
maintain potency for at least 12 months, and cur-
rent recommendations state that purchased extracts
should therefore be replaced annually. Guidelines
argue against the mixing of allergens with high pro-
tease activity (such as mould and cockroach aller-
gens) with those of low activity (grass, tree, weed,
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Table 4  Recommended Maintenance Doses for Aeroallergen Immunotherapy
Dose in Dose of Maintenance
Allergen Standardized Units Major Allergen Concentrate* (w/v)
Dermatophagoides 600 AU 7–12 g Der p 1 NA
pteronyssinus
Dermatophagoides 2,000 AU 10 g Der f 1 NA
farinae
Cat dander 2,000–3,000 BAU 11–17 g Fel d 1 NA
Grass 4,000 BAU 7–20 g Phi p 5 NA
Short ragweed NA 6–24 g Amb a 1 1:100–1:30
Other pollen NA ND 1:100–1:30
(nonstandardized)
Fungi/mould NA ND 1:100–1:50
Adapted from Nelson HS3; Joint Task Force on Practice Parameters5; Nelson HS.48
AU = allergy units; BAU = bioequivalent allergy units; NA = not applicable; ND = not determined; w/v = weight per
volume.
*Based on a maintenance injection of 0.5 mL.
cat, and dog allergens). Glycerinated extracts have
the greatest stability and may also act to protect
the allergens from proteases.
Current recommendations are that inhalant
allergen IT be discontinued after 3 to 5 years.5 The
most important randomized controlled trial to
examine the persistence of improved symptoms
after discontinuation of IT was the grass SAR
study previously discussed.16 This study demon-
strated that the IT-induced relief of grass pollen
rhinitis symptoms persisted for a minimum of 3
years after discontinuation of IT. No differences
were observed between those patients who con-
tinued with IT and those who discontinued IT
after the completion of 3 years of therapy. Per-
sistence of improved symptoms after discontinu-
ation of dust mite IT has also been shown17
although not in a double-blind placebo-controlled
trial. Whether IT with other aeroallergens will
have the same prolonged protective effects as IT
with grass or dust mite allergen has not been deter-
mined. Patients will have achieved all of the clin-
ical benefit they can expect from a given extract
after 3 to 5 years. Insufficient response to that
extract clearly warrants its discontinuation and a
reassessment of the diagnosis of AR, the contin-
uing relevance of allergens present in that extract,
and the adequacy of dosing of each allergen.
Recrudescence of symptoms after IT is discon-
tinued would also warrant a reevaluation of the
patient’s allergies and suggests that IT may need
to be restarted with different agents or with doses
that are more appropriate; if allergies to the same
allergens remain responsible for the recurrent
symptoms, this argues that the repeat IT should be
maintained for a longer duration.
Safety Issues
From local reaction to systemic anaphylaxis and
death, the risks from IT require vigilance from
physicians, ancillary staff, and the patients them-
selves. In the United States, severe reactions are
rare; estimates range from < 1% of patients who
receive conventional IT to > 36% of patients in
some studies of IT using “rush” regimens involv-
ing accelerated buildup of the IT to maintenance
doses over a 1 or 2 day period.38,39 In a recent
review, 41 IT fatalities from 1990 to 2001 were
reported, for an average of 3.4 fatal IT reactions
per year.40 Surprisingly, although incorrect allergy
injections were not identified in this study as a
cause of death, a survey of allergists’ experiences
with incorrect allergy injections found that injec-
tions given either to the wrong patient or to the cor-
rect patient but involving an incorrect dilution or
volume were responsible for a systemic reaction
rate of approximately 32%.41 Table V outlines risk
factors for systemic reactions to immunotherapy.
Poorly controlled asthma stands as the most sig-
nificant risk factor for severe systemic reactions to
IT (this is also true for all forms of anaphylaxis).
Several studies3 reported the presence of moder-
ate or severe asthma in the vast majority of reported
IT fatalities.38,42 More recently, Bernstein and col-
leagues found that 15 of 17 IT fatality patients
had preexisting asthma40; 60% of these patients
were reported to have suboptimal control of their
asthma symptoms despite appropriate pharma-
cotherapy. Additionally, 50% of the asthma fatal-
ity patients in this study (for whom data were
available) demonstrated a forced expiratory volume
in 1 second (FEV1) of < 70% prior to injection. The
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Table 5  Risk Factors for Systemic Reactions to Allergen Immunotherapy
Asthma: poorly controlled or moderate to severe by classification
Administration of immunotherapy in medically unsupervised or unprepared clinical setting
Failure to administer epinephrine
Incorrect injection
Lack of enforcement of the recommended 20- to 30-minute waiting period
Comorbid medical conditions (ie, cardiovascular disease or nonallergic respiratory disease)
Coadministration of pharmacologic therapies: -blockers (possibly ACE inhibitors)
Medical noncompliance
ACE = angiotensin-converting enzyme.
absence of recent spirometric or even peak flow
data for many of these patients emphasizes the
importance of obtaining this information on all
asthmatic patients prior to administering each IT
injection. Symptomatic patients, patients with a
recent history of hospitalization or emergency
department visits, and patients who have suffered
a recent exacerbation of asthma represent the
majority of fatal reactors in surveys of the safety
of IT. In addition to spirometry or peak flow assess-
ment, preinjection assessments of recent asthma
symptoms, rescue inhaler use, nocturnal awaken-
ings, recent health care utilization, and medication
compliance are vital for ensuring safe IT for asth-
matic patients. Careful selection of patients and the
identification of patients with moderate or severe
asthma and labile asthma will greatly reduce the
risk of fatal systemic reactions to IT.
The potential for severe systemic reactions fol-
lowing IT injections necessitates the administra-
tion of IT in a proper clinical setting. The home
and other medically unsupervised settings are
inappropriate venues for IT; out-of-office admin-
istration has been associated with death, likely
because of the lack of recognition of systemic
reactions and the failure to administer epinephrine
in a timely fashion. Guidelines recommend that
injections be given at the prescribing allergist’s
office or at the office of another physician who is
trained and medically equipped for the treatment
of systemic IT reactions. Delayed administration
of epinephrine is consistently reported as a risk fac-
tor for IT fatality. In general, epinephrine (1:1000)
should be premeasured and instantly available for
intramuscular administration should a systemic
reaction occur. Physicians who administer IT sup-
plied to them by an allergist must be provided with
specific instructions  emphasizing the importance
of prompt administration of epinephrine and other
resuscitative measures to ensure the safety.
Physicians must enforce the recommended
20- to 30-minute waiting period following an IT
injection. In general, 20 minutes is considered
sufficient for patients with AR alone whereas asth-
matic patients should remain at least 30 minutes
after an IT injection. However, up to 38% of sys-
temic reactions occur after 30 minutes and thus out-
side the clinician’s office. Current recommenda-
tions advise a prolonged postinjection waiting
period for patients with a history of systemic reac-
tions after the half-hour waiting period.5 Although
no more-specific recommendations exist, these
observations argue for the appropriateness of
more-prolonged waiting periods for patients with
more than mild asthma or with a history of a pre-
vious systemic reaction. In addition, it has been
suggested that any patient with a history of a pre-
vious systemic reaction or perhaps even all asth-
matic patients receiving IT should be prescribed
epinephrine and should receive appropriate train-
ing in its indications and administration.
Patient-specific IT vials and administration
forms may reduce the risk of incorrect IT injec-
tions. As 32% of incorrect IT injections potentially
lead to systemic reactions, specific steps must be
taken at each patient encounter to ensure safety.
One suggested approach involves a “one patient,
one nurse, one injection” safety measure. One
nurse and the patient review three identifiers,
including first and last names on the patient-
specific IT vial and administration form, as well
as the patient’s date of birth or medical record num-
ber. An additional recommendation is to use stan-
dardized color-coded IT vials according to strength
(from most dilute to maintenance strength). Finally,
clinic physicians should be informed immediately
should there be any deviation from an appropri-
ate injection dose.
On initial and follow-up evaluations of patients
with AR or allergic asthma, close attention to
comorbid medical conditions and coadministration
of pharmacologic therapies are essential for safe
IT. Patients may have heart disease or hyperten-
sion requiring medications such as -blockers or
angiotensin-converting enzyme inhibitors, both
of which have been implicated in fatal reactions
to IT.5,38,40 Advanced age, nonallergic respiratory
disease, or risk factors for cardiovascular disease
such as hypertension, elevated cholesterol, or dia-
betes should be weighed in risk-benefit analyses
because administration of epinephrine for sys-
temic reactions may induce significant cardio-
vascular side effects. These patients may also
have a reduced ability to survive a systemic reac-
tion. Although not addressed here, Hymenoptera
IT benefits may outweigh risk in patients taking
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-blockers insofar as these patients are unlikely
to be able to completely avoid stings in the future
and are at less risk from the complications of a sys-
temic reaction in a physician’s office than they
would be in the field after being stung.
Future Immunotherapy Strategies
Future strategies for IT are aimed at delivering
increased efficacy with less risk of IgE-mediated
systemic side effects. Recognition of the impor-
tance of T-cell–dependent mechanisms in
immunomodulation after IT has led to studies to
develop reagents that interact with T lymphocytes
without engaging mast cell/basophil–bound IgE.
Denatured proteins such as polymerized extracts
or, more recently, short peptide fragments derived
from genetically-engineered allergens have been
successfully used in IT studies. These peptides
retain the ability to be recognized and processed
by antigen-presenting cells, to be presented to T
helper lymphocytes, and to drive T cells into an
anergic or tolerant state. Because these short
peptides lack the complex structure of their par-
ent compounds, they cannot be recognized by
mast cell/basophil–bound IgE and are generally
not associated with risk for immediate-phase
anaphylactic responses. Studies of peptides in
patients sensitized to cats43,44 and to bee venom45
have demonstrated reductions in the proliferation
of CD4+ T cells, diminished Th1 and Th2 cytokine
production, and significant increases in IL-10.
However, these compounds have been frustrated
by their tendency initially to activate allergen-
specific Th2-like cells and thereby produce
delayed but often severe allergic reactions, includ-
ing exacerbations of asthma.46 More recent stud-
ies have used allergenic peptides coupled to syn-
thetic bacterial deoxyribonucleic acid (DNA)
sequences.47 These are based on the concept that
engagement of these immunostimulatory DNA
sequences to their specific toll-like 9 (TL9) recep-
tors will be a potent signal to drive the ensuing
immune responses toward Th1 immunity. Ini-
tial studies were extremely promising in regard
to efficacy, safety, and long-term immunomod-
ulation with these agents. Interestingly, the
absence of adverse effects associated with the
Th1-like responses appears to be related to a
concomitant induction of regulatory immune
responses.
A final and potentially more immediately
available possibility involves the concurrent admin-
istration of humanized anti-IgE (omalizumab)
with standard IT. The concept is that the removal
of IgE should dramatically reduce the risk of ana-
phylactic reactions and thereby may allow a more
rapid induction of tolerance, the implementation
of higher doses of allergen, or the administration
of IT to patients who are considered to have con-
traindications to IT. For example, it may become
easier to administer IT to patients with moderate
to severe asthma or with a previous history of
systemic reactions. Recent studies support such an
approach and raise the exciting potential of a role
for IT in patients for whom immunomodulating
therapies might provide critically important clin-
ical benefits.
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